WHEN BEHAVIOR MATTERS
The Behavioral Measurement Shared Resource (BMSR) provides OSUCCC – James investigators with a continuum of services that includes planning and developing research proposals and projects, data collection and behavioral data interpretation to help them integrate behavioral research into their studies.
Director Michael Slater, PhD, MPA, is a member of the OSUCCC – James Cancer Control Program and a Social and Behavioral Sciences Distinguished Professor in Ohio State's School of Communication. He has served as principal investigator on NIH-funded studies representing more than $11 million in research grants and has more than 100 publications, mostly in the areas of communication and health behavior and research methodology.
Associate Director Paul Reiter, PhD, is a member of the OSUCCC – James Cancer Control Program and an assistant professor in Ohio State's College of Medicine, Division of Cancer Prevention and Control. His research focuses largely on cancer prevention and control through screening and vaccination.
The BMSR assists in designing and incorporating behavioral variables into proposed or ongoing research. The shared resource can help with the accrual of underserved groups into research studies, in designing and implementing assessment tools suited to the investigator's aims and hypotheses, and in the interpretation of behavioral data for publication.
The BMSR offers services in:
• Research design
• Population-based data retrieval
• Recruitment and accrual, particularly with underserved and minority populations
• Behavioral assessment
• Data collection
The BMSR also collaborates with investigators at outside institutions, assisting in the design and development of data collection forms and processes, recruitment of study participants, interviewer training and data-analysis preparation. For more information, visit the Behavioral Measurement Shared Resource website at http://cancer.osu.edu/research/cancerresearch/sharedresources/bm/pages/index.aspx.
EXPERIMENTAL THERAPEUTICS PROGRAM HAS SPACE TO CALL ITS OWNE
The move is another step toward an Ohio State drug-discovery institute
ABOVE: The OSUCCC – James Experimental Therapeutics Program is occupying new laboratory and office space in The Ohio State University Wexner Medical Center Biomedical Research Tower
The burgeoning OSUCCC – James efforts in drug discovery and design took a significant step forward in May when investigators in the cancer center's Experimental Therapeutics Program began occupying new space on the fourth floor of the 12th Avenue Biomedical Research Tower.
The 25,640 sq. ft. area – nearly 80 percent of which is laboratory space – is the research program's coordinating center, says Michael Grever, MD, co-leader of the Experimental Therapeutics Program and professor and chair of the Department of Internal Medicine. "This new space is designed to be a hub for new ideas and improved strategies for the treatment of cancer."
The drug discovery and development unit is ideally located between Ohio State's new James Cancer Hospital and Solove Research Institute and College of Pharmacy, and across the street from the research laboratories of the Dorothy M. Davis Heart and Lung Research Institute.
"Our location helps us tap into the expertise and talents of a range of people on campus who are interested in drug development," Grever says.
Overall, the Experimental Therapeutics Program is composed of more than 50 clinical and laboratory investigators from 16 departments within Ohio State's College of Medicine and College of Pharmacy. Only a portion of them are housed in the new area. Research under way in the unit includes work in epigenetic therapeutics, biomarkers and targeted therapies for lung cancer, and development of a natural-products anticancer agent. It also houses an office for the cancer program's emerging drug development program, and space is reserved for the recruitment of new investigators involved in experimental therapeutics research. Embedded in this research area are three key supporting core services:
• The Medicinal Chemistry Shared Resource, which offers expertise in synthetic and process chemistry, molecular pharmacology, purity analyses and custom syntheses.
• The Pharmacoanalytic Shared Resource, which provides high- quality, cost-effective method development, quantitative sample analysis, and pharmacokinetic, pharmacodynamic and pharmacogenetic experimental design and data analysis.
• The Solid Tumor Translational Science Shared Resource, which develops customizable validation assays to provide innovative correlative-science studies associated with early-phase solid-tumor oncology clinical trials. "In addition to laboratory and office space and essential core services for therapeutics research, we provide open spaces and conference rooms to encourage and facilitate creative interactions among investigators," Grever says. "The Ohio State cancer program is building a truly robust drug discovery and development program."
August 10-12, 2012
FOCUS: Pelotonia is an annual bicycling event that takes riders through bucolic Ohio countryside on routes of varying length. The event attracts thousands of cyclists from across the nation, and 100 percent of the money raised supports cancer research at the OSUCCC – James.
For information or to register as a rider or volunteer, visit www.pelotonia.org.
CANCER CACHEXIA: MOLECULAR MECHANISMS
AND THERAPEUTIC APPROACHES
Sept. 21-23, 2012, Boston, Mass.
FOCUS: The clinical manifestations of cancer cachexia; mechanisms of skeletal and cardiac muscle wasting in cancer cachexia; common mechanisms of cachexia-promoting conditions; the significance of non-muscle tissue in cancer cachexia; and optimal strategies for treating cancer cachexia.
To register, view the agenda and submit an abstract, visit http://cancer.convio.net/site/R?i=HzAMfbMeO7s7RuBvm2XbrQ.
STATE-OF-THE-ART ENDOSCOPIC SKULL BASE
SURGERY: A HANDS-ON COURSE
Oct. 25-28, 2012 GREATER COLUMBUS CONVENTION CENTER
FOCUS: This course for neurosurgeons, head-and-neck surgeons and other skull-base surgeons covers current indications, limitations and surgical techniques for endoscopic endonasal surgery of the skull base, pituitary fossa, orbit and craniocervical junction, and for the supraorbital keyhole craniotomy approach.
For more information, contact Pat Fitzwater at Academic Event Management (805) 300-9154, or by email at firstname.lastname@example.org.